logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
R

Ronald Kates

University of Cologne
H指数:42
被引数:6,721

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT

Braun, M.; Gluz, O.; Kuemmel, S.; Nitz, U.; Luedtke-Heckenkamp, K.; Darsow, M.; Forstbauer, H.; Polata, S.; Grischke, E.M.; Uleer, C.; et al. 优化辅助CDK4/6抑制剂的危险度评估：超越试验纳入标准，根据ADAPT整合复发评分和内分泌应答。Breast Care 2026. online ahead of print. [Google Scholar] [CrossRef]

Breast Care
IF2.1
2026-02-010
PRE
Braun, Michael; Gluz, Oleg; Kuemmel, Sherko; Nitz, Ulrike; Luedtke-Heckenkamp, Kerstin; Darsow, Maren; Forstbauer, Helmut; Polata, Silke; Grischke, Eva-Maria; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Zu Eulenburg, Christine; Kates, Ronald; Burmeister, Sandy; Graeser, Monika; Wuerstlein, Rachel; Baehner, Rick; Christgen, Matthias; Kreipe, Hans Heinrich; Harbeck, Nadia
A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding “Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/ HER2-negative breast cancer” by Chen et al.

两种试验的故事：TAILORx和PlanB。关于Chen等人撰写的“基因组高风险、淋巴结阴性、HR阳性/HER2阴性乳腺癌中蒽环类药物的影响”一文的致编辑函。

Annals of Oncology
IF65.4
2025-12-200
PRE
Oleg Gluz; Ronald Kates; Sherko Kuemmel; Ulrike Nitz; Nadia Harbeck
Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer

RNA表达特征与复发基因组改变的整合分析：治疗前与绝经状态、短期内分泌治疗反应及无病生存期的关联性研究（在腔面乳腺癌中）

ESMO Open
IF8.3
2025-11-210
OAAI
G. Zhang; H. Ni; L. Mishieva; S. Bartels; M. Christgen; H. Christgen; L.D. Kandt; M. Raap; R.E. Kates; O. Gluz; M. Graeser; S. Kümmel; U. Nitz; C. Plass; U. Mansmann; C. zu Eulenburg; C. Gerhäuser; H.H. Kreipe; N. Harbeck
A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders

一个预测性内分泌抵抗指数能够准确地对腔面型乳腺癌治疗反应者和非反应者进行分层。

JOURNAL OF CLINICAL INVESTIGATION
IF13.6
2025-10-012
OA
Zhang, Guokun; Jurinovic, Vindi; Bartels, Stephan; Christgen, Matthias; Christgen, Henriette; Kandt, Leonie Donata; Mishieva, Lidiya; Ni, Hua; Raap, Mieke; Klein, Janin; Katzke, Anna-Lena; Hofmann, Winfried; Steinemann, Doris; Kates, Ronald E.; Gluz, Oleg; Graeser, Monika; Kummel, Sherko; Nitz, Ulrike; Plass, Christoph; Lehmann, Ulrich; Eulenburg, Christine zu; Mansmann, Ulrich; Gerhauser, Clarissa; Harbeck, Nadia; Kreipe, Hans H.
Endocrine response assessment in HR-positive HER2-negative early breast cancer: concordance of local versus central Ki67 measurements in the WSG ADAPTcycle trial (n = 5292)

内分泌反应评估在HR阳性HER2阴性早期乳腺癌中的应用：WSG ADAPTcycle试验（n=5292）中局部与中央Ki67测量的符合情况

ESMO Open
IF8.3
2025-08-140
OAAI
M. Hamann; M. Christgen; O. Gluz; U. Nitz; S. Kuemmel; M. Braun; M. Thill; R. Wuerstlein; P. Wimberger; A. Hartkopf; C. Schem; M. Zaiss; V. Bjelic-Radisic; M. Just; K. Veselinovic; M. Vincent; M. Graeser; K. Krauss; O. Hoffmann; K. Lüdtke-Heckenkamp; R.E. Kates; C. zu Eulenburg; K. Jóźwiak; S. Burmeister; M. Hauptmann; F. Baehner; P. Schmid; H.-H. Kreipe; N. Harbeck
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials

HER2+早期乳腺癌降级新辅助治疗后生存预测：一项基于三项WSG试验的合并分析

Annals of Oncology
IF65.4
2025-08-050
PREAI
M. Graeser; O. Gluz; C. Zu Eulenburg; S. Kuemmel; R. von Schumann; M. Christgen; R. Wuerstlein; E. Pelz; H.H. Kreipe; P. Schmid; M. Thill; M. Braun; J. Potenberg; C. Schumacher; J. Tio; J. Schumacher; L. Wujak; A.D. Hartkopf; M. Just; C. Schem; K. Luedtke-Heckenkamp; F. Hilpert; A. Kentsch; R.E. Kates; U. Nitz; N. Harbeck
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer A Secondary Analysis of a Randomized Clinical Trial

三阴性乳腺癌患者中的基因改变、治疗反应和生存情况：一项随机临床试验的二次分析

JAMA NETWORK OPEN
IF9.7
2025-02-260
OA
Richters, Lisa; Gluz, Oleg; Weber-Lassalle, Nana; Christgen, Matthias; Haverkamp, Heinz; Kuemmel, Sherko; Kayali, Mohamad; Kates, Ronald E.; Grischke, Eva-Maria; Altmueller, Janine; Forstbauer, Helmut; Thiele, Holger; Braun, Michael; Warm, Mathias; Ossowski, Anna; Wuerstlein, Rachel; Ernst, Corinna; Graeser, Monika; Linn, Sabine C.; Nitz, Ulrike; Hauke, Jan; Kreipe, Hans Heinrich; Schmutzler, Rita K.; Hahnen, Eric; Harbeck, Nadia
Evaluation of therapy support through a standardized nursing consultation for patients undergoing oral tumor therapy in gynecological oncology within the prospective CAMPA initiative

通过前瞻性CAMPA倡议中标准化的护理咨询，对妇科肿瘤学中接受口腔肿瘤治疗的患者的治疗支持进行评估。

EUROPEAN JOURNAL OF ONCOLOGY NURSING
IF2.7
2025-02-010
PRE
Hirschberg, Lisa; Henze, Franziska; Paradies, Kerstin; Winkler, Sophie; Schinkoethe, Timo; Haidinger, Renate; Kates, Ronald; Hempel, Dirk; Mahner, Sven; Kost, Bernd; Koenig, Alexander; Lippach, Kristina; Trillsch, Fabian; Theurich, Sebastian; Harbeck, Nadia; Milani, Valeria; Wuerstlein, Rachel
Survival outcome of neoadjuvant endocrine therapy plus trastuzumab and pertuzumab (ET plus T plus P) vs. de-escalated chemotherapy (CT) plus T plus P in hormone receptor positive (HR+)/HER2+early breast cancer (EBC): WSG-TP-II trial

内分泌新辅助治疗联合曲妥珠单抗和帕妥珠单抗（ET plus T plus P）与降级化疗（CT）联合曲妥珠单抗和帕妥珠单抗（T plus P）在激素受体阳性（HR\(+\)/HER2\(+\)）早期乳腺癌（EBC）中的生存结局：WSG-TP-II试验

ANNALS OF ONCOLOGY
IF65.4
2024-09-011
PRE
Gluz, O.; Nitz, U. A.; Christgen, M.; Kummel, S.; Holtschmidt, J.; Schumacher, J.; Hartkopf, A. D.; Luedtke-Heckenkamp, K.; Just, M.; von Schumann, R.; Polata, S.; Schinkoethe, T.; Graeser-Mayer, M. K.; Kates, R. E.; Wuerstlein, R.; Kreipe, H.; Harbeck, N.
Individual patient data meta-analysis of clinical and translational biomarkers for prediction of pathological complete response (pCR) after de-escalated therapy in HER2+breast cancer in four trials of the West German Study Group
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Graeser, Monika; Gluz, Oleg; zu Eulenburg, Christine; Kuemmel, Sherko; von Schumann, Raquel; Christgen, Matthias; Wuerstlein, Rachel; Pelz, Enrico; Kreipe, Hans-Heinrich; Schmid, Peter; Thill, Marc; Braun, Michael; Potenberg, Jochem; Schumacher, Claudia; Tio, Joke; Hartkopf, Andreas; Just, Marianne; Schem, Christian; Ludtke-Heckenkamp, Kerstin; Grischke, Eva-Maria; Hilpert, Felix; Kentsch, Angela; Kates, Ronald; Nitz, Ulrike; Harbeck, Nadia
Multi-modal artificial intelligence models from baseline histopathology predict prognosis in HR+HER2-early breast cancer
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Kates-Harbeck, Daniel; Kreipe, Hans-Heinrich; Gluz, Oleg; Christgen, Matthias; Kuemmel, Sherko; Graeser, Monika; Nitz, Ulrike; Mahner, Sven; Mayr, Doris; Wuerstlein, Rachel; Mitani, Akinori; Zhang, Jingbin; Pinckaers, Hans; Ren, Yi; Wood, Peter; Griffin, Jacqueline; Feng, Felix; Esteva, Andre; Keim-Malpass, Jess; Kates, Ronald; Harbeck, Nadia
Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter ADAPTcycle trial (n=4,334)
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Gluz, Oleg; Christgen, Matthias; Nitz, Ulrike; Kuemmel, Sherko; Braun, Michael; Thill, Marc; Wuerstlein, Rachel; Wimberger, Pauline; Hartkopf, Andreas; Schem, Christian; Zaiss, Matthias; Bjelic-Radisic, Vesna; Just, Marianne; Veselinovic, Kristina; Vincent, Myriam; Graeser, Monika; Krauss, Katja; Hoffmann, Oliver; Ludtke-Heckenkamp, Kerstin; Kates, Ronald; zu Eulenburg, Christine; Jozwiak, Katarzyna; Burmeister, Sandy; Baehner, Rick; Schmid, Peter; Kreipe, Hans-Heinrich; Harbeck, Nadia
Impact of age and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): Results from the multicenter WSG-ADAPTcycle trial (n=5,290)
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Gluz, Oleg; Christgen, Matthias; Nitz, Ulrike; Kuemmel, Sherko; Braun, Michael; Thill, Marc; Wuerstlein, Rachel; Wimberger, Pauline; Hartkopf, Andreas; Schem, Christian; Zaiss, Matthias; Bjelic-Radisic, Vesna; Just, Marianne; Veselinovic, Kristina; Vincent, Myriam; Graeser, Monika; Krauss, Katja; Hoffmann, Oliver; Ludtke-Heckenkamp, Kerstin; Kates, Ronald; Eulenburg, Christine Zu; Schmid, Peter; Baehner, Rick; Kreipe, Hans-Heinrich; Harbeck, Nadia
HER2DX genomic assay in triple-negative breast cancer (TNBC) patients treated with 12-weeks of neoadjuvant chemotherapy: a correlative analysis from WSGADAPT-TN phase II trial
CANCER RESEARCH
IF16.6
2024-05-020
PRE
Gluz, Oleg; Braso-Maristany, Fara; Nitz, Ulrike; Pare, Laia; Christgen, Matthias; Villacampa, Guillermo; Conte, Benedetta; Kuemmel, Sherko; Kates, Ronald; Kolberg-Liedtke, Cornelia; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Vivancos, Ana; Wuerstlein, Rachel; Parker, Joel S.; Graeser, Monika; Perou, Charles M.; zu Eulenburg, Christine; Villagrasa, Patricia; Kreipe, Hans-Heinrich; Prat, Aleix; Harbeck, Nadia
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy
CANCER TREATMENT REVIEWS
IF10.5
2023-12-014
PRE
Harbeck, Nadia; Kates, Ronald; Schinkoethe, Timo; Schumacher, Johannes; Wuerstlein, Rachel; Degenhardt, Tom; Lueftner, Diana; Raeth, Philip; Hoffmann, Oliver; Lorenz, Ralf; Decker, Thomas; Reinisch, Mattea; Goehler, Thomas; Staib, Peter; Gluz, Oleg; Fasching, Peter A.; Schmidt, Marcus
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HRD HER2L metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial
ANNALS OF ONCOLOGY
IF65.4
2023-08-0116
OA
Harbeck, N.; Fasching, P. A.; Wuerstlein, R.; Degenhardt, T.; Lueftner, D.; Kates, R. E.; Schumacher, J.; Raeth, P.; Hoffmann, O.; Lorenz, R.; Decker, T.; Reinisch, M.; Goehler, T.; Staib, P.; Gluz, O.; Schinkoethe, T.; Schmidt, M.
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2L early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2L trial
ANNALS OF ONCOLOGY
IF65.4
2023-06-012
PRE
Gluz, O.; Kuemmel, S.; Nitz, U.; Braun, M.; Luedtke-Heckenkamp, K.; von Schumann, R.; Darsow, M.; Forstbauer, H.; Potenberg, J.; Uleer, C.; Grischke, E. M.; Aktas, B.; Schumacher, C.; zu Eulenburg, C.; Kates, R.; Jozwiak, K.; Graeser, M.; Wuerstlein, R.; Baehner, R.; Christgen, M.; Kreipe, H. H.; Harbeck, N.
Combined biomarker analysis for prediction of pathological complete response (pCR) after 12 weeks of pembrolizumab plus trastuzumab plus pertuzumab in HER2-enriched early breast cancer: Keyriched-1 trial
CANCER RESEARCH
IF16.6
2023-03-010
PRE
Graeser, Monika; Kuemmel, Sherko; Gluz, Oleg; Feuerhake, Friedrich; Volk, Valery; Ulbrich-Gebauer, Daniel; Biehl, Claudia; Reinisch, Mattea; Kostara, Athina; Scheffen, Iris; Luedtke-Heckenkamp, Kerstin; Hartkopf, Andreas; Hilpert, Felix; Kentsch, Angela; Ziske, Carsten; Depenbusch, Reinhard; Braun, Michael; Blohmer, Jens-Uwe; Eulenburg, Christine Zu; Christgen, Matthias; Kates, Ronald; Bartels, Stephan; Kreipe, Hans-Heinrich; Pelz, Enrico; Schmid, Peter; Harbeck, Nadia

研究方向

暂未获取到该数据
N
Nadia Harbeck
H 指数:131论文数:2,063被引数:8.5万
O
Oleg Gluz
H 指数:38论文数:417被引数:6,724
U
Ulrike Nitz
H 指数:39论文数:401被引数:1.3万
R
Rachel Wuerstlein
H 指数:38论文数:475被引数:5,749
M
Matthias Christgen
H 指数:38论文数:245被引数:5,349
M
Michael Braun
H 指数:46论文数:388被引数:8,311
S
Sherko Küemmel
H 指数:33论文数:234被引数:5,350
H
Hans Kreipe
H 指数:78论文数:712被引数:2.4万
B
Bahriye Aktas
H 指数:42论文数:511被引数:8,707
D
Doris Augustin
H 指数:18论文数:154被引数:1,725